|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
24
|
|
pubmed:dateCreated |
2005-8-19
|
|
pubmed:abstractText |
This multicenter phase II study was undertaken to define the efficacy and safety of cetuximab, an antiepidermal growth factor receptor chimeric human and murine monoclonal antibody, administered with cisplatin to patients with refractory metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN).
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
20
|
|
pubmed:volume |
23
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5578-87
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:16009949-Adult,
pubmed-meshheading:16009949-Aged,
pubmed-meshheading:16009949-Aged, 80 and over,
pubmed-meshheading:16009949-Antibodies, Monoclonal,
pubmed-meshheading:16009949-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16009949-Carcinoma, Squamous Cell,
pubmed-meshheading:16009949-Cisplatin,
pubmed-meshheading:16009949-Disease Progression,
pubmed-meshheading:16009949-Drug Administration Schedule,
pubmed-meshheading:16009949-Female,
pubmed-meshheading:16009949-Fluorouracil,
pubmed-meshheading:16009949-Head and Neck Neoplasms,
pubmed-meshheading:16009949-Humans,
pubmed-meshheading:16009949-Logistic Models,
pubmed-meshheading:16009949-Male,
pubmed-meshheading:16009949-Middle Aged,
pubmed-meshheading:16009949-Neoplasm Recurrence, Local,
pubmed-meshheading:16009949-Paclitaxel,
pubmed-meshheading:16009949-Survival Analysis,
pubmed-meshheading:16009949-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
|
|
pubmed:affiliation |
Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Unit 432, PO Box 301402, Houston, TX 77230-1402, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Multicenter Study,
Clinical Trial, Phase II
|
